Add time:09/26/2019 Source:sciencedirect.com
In the early 1950s, tacrine was used experimentally to reverse cholinergic coma in animals. In 1993, the US Food and Drug Administration approved tacrine for the treatment of mild to moderate Alzheimer's disease. Tacrine causes reversible acetylcholinesterase inhibition in the brain, and thereby boosts the level of acetylcholine to sustain memory. In addition, tacrine blocks sodium and potassium channels. At a therapeutic dose, tacrine causes liver toxicity. Tacrine-induced hepatotoxicity is due to oxidative stress. Treatment rests with use of atropine, antioxidants, and other symptomatic measures. Tacrine is no longer indicated for Alzheimer's treatment.
We also recommend Trading Suppliers and Manufacturers of TACRINE HYDROCHLORIDE (cas 1684-40-8). Pls Click Website Link as below: cas 1684-40-8 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View